Your browser doesn't support javascript.
loading
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Tesileanu, C Mircea S; Sanson, Marc; Wick, Wolfgang; Brandes, Alba A; Clement, Paul M; Erridge, Sara C; Vogelbaum, Michael A; Nowak, Anna K; Baurain, Jean-Francois; Mason, Warren P; Wheeler, Helen; Chinot, Olivier L; Gill, Sanjeev; Griffin, Matthew; Rogers, Leland; Taal, Walter; Rudà, Roberta; Weller, Michael; McBain, Catherine; van Linde, Myra E; Aldape, Kenneth; Jenkins, Robert B; Kros, Johan M; Wesseling, Pieter; von Deimling, Andreas; Hoogstrate, Youri; de Heer, Iris; Atmodimedjo, Peggy N; Dubbink, Hendrikus J; Brouwer, Rutger W W; van IJcken, Wilfred F J; Cheung, Kin Jip; Golfinopoulos, Vassilis; Baumert, Brigitta G; Gorlia, Thierry; French, Pim J; van den Bent, Martin J.
Afiliación
  • Tesileanu CMS; Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Sanson M; Sorbonne Université, Inserm, CNRS, UMR S 1127, Paris Brain Institute - Institut du Cerveau (ICM), AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France.
  • Wick W; Neurology Department, University of Heidelberg, and Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Brandes AA; Medical Oncology Department, AUSL-IRCCS Scienze Neurologiche, Bologna, Italy.
  • Clement PM; Oncology Department, KU Leuven and General Medical Oncology Department, UZ Leuven, Leuven Cancer Institute, Leuven, Belgium.
  • Erridge SC; Edinburgh Centre for Neuro-Oncology, Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom.
  • Vogelbaum MA; Neuro-Oncology Department, Moffitt Cancer Center, Tampa, Florida.
  • Nowak AK; Medical School, University of Western Australia, Crawley, Western Australia.
  • Baurain JF; Medical Oncology Department, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, Western Australia.
  • Mason WP; CoOperative Group for NeuroOncology, University of Sydney, New South Wales, Australia.
  • Wheeler H; Medical Oncology Department, King Albert II Cancer Institute, Cliniques universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
  • Chinot OL; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Gill S; Northern Sydney Cancer Centre, University of Sydney, St Leonards, New South Wales, Australia.
  • Griffin M; Aix-Marseille University, AP-HM, Neuro-Oncology division, Marseille, France.
  • Rogers L; Medical Oncology Department, Alfred Hospital, Melbourne, Australia.
  • Taal W; Clinical Oncology Department, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
  • Rudà R; Radiation Oncology Department, Gammawest Cancer Services, Salt Lake City, Utah.
  • Weller M; Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • McBain C; Neuro-Oncology Department, City of Health and Science Hospital and University of Turin, Turin, Italy.
  • van Linde ME; Neurology Department, Clinical Neuroscience Center, University Hospital and University of Zurich, Zurich, Switzerland.
  • Aldape K; Clinical Oncology Department, The Christie NHS FT, Manchester, United Kingdom.
  • Jenkins RB; Medical Oncology Department, Brain Tumor Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Kros JM; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Wesseling P; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
  • von Deimling A; Pathology Department, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Hoogstrate Y; Pathology Department, Amsterdam University Medical Centers, Amsterdam, the Netherlands.
  • de Heer I; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Atmodimedjo PN; Neuropathology Department, Ruprecht-Karls-University, and CCU Neuropathology German Cancer Institute and Consortium, DKFZ, and DKTK, Heidelberg, Germany.
  • Dubbink HJ; Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Brouwer RWW; Neurology Department, Brain Tumor Center, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • van IJcken WFJ; Pathology Department, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Cheung KJ; Pathology Department, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
  • Golfinopoulos V; Center for Biomics, Erasmus MC, Rotterdam, the Netherlands.
  • Baumert BG; Center for Biomics, Erasmus MC, Rotterdam, the Netherlands.
  • Gorlia T; EORTC HQ, Brussels, Belgium.
  • French PJ; EORTC HQ, Brussels, Belgium.
  • van den Bent MJ; Radiation-Oncology Department (MAASTRO), Maastricht University Medical Center (MUMC) and GROW (School for Oncology), Maastricht, the Netherlands.
Clin Cancer Res ; 28(12): 2527-2535, 2022 06 13.
Article en En | MEDLINE | ID: mdl-35275197
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Astrocitoma / Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Astrocitoma / Neoplasias Encefálicas / Glioblastoma Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Estados Unidos